YMAB
Y-mAbs Therapeutics
YMAB
YMAB
Delisted
YMAB was delisted on the 15th of September, 2025.
85 hedge funds and large institutions have $95.4M invested in Y-mAbs Therapeutics in 2023 Q1 according to their latest regulatory filings, with 13 funds opening new positions, 32 increasing their positions, 27 reducing their positions, and 19 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more capital invested
Capital invested by funds: $ → $
more funds holding in top 10
Funds holding in top 10: →
0.73% less ownership
Funds ownership: 44.21% → 43.48% (-0.73%)
7% less funds holding
Funds holding: 91 → 85 (-6)
32% less first-time investments, than exits
New positions opened: 13 | Existing positions closed: 19
Holders
85
Holding in Top 10
1
Calls
$50K
Puts
$2K
Top Buyers
| 1 | +$2.15M | |
| 2 | +$1.62M | |
| 3 | +$1.61M | |
| 4 |
Nuveen Asset Management
Chicago,
Illinois
|
+$1.15M |
| 5 |
Acadian Asset Management
Boston,
Massachusetts
|
+$1.01M |
Top Sellers
| 1 | -$3.28M | |
| 2 | -$2.53M | |
| 3 | -$1.95M | |
| 4 |
BlackRock
New York
|
-$1.09M |
| 5 |
E
Ergoteles
New York
|
-$936K |